{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T18:47:39Z","timestamp":1763837259900,"version":"3.37.3"},"reference-count":60,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"Oxford PharmaGenesis"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2021,4,16]]},"DOI":"10.1080\/10428194.2020.1864352","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T06:48:59Z","timestamp":1610606939000},"page":"1066-1076","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia"],"prefix":"10.1080","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"first","affiliation":[{"name":"Division of Experimental Oncology, Strategic Research Program on Chronic Lymphocytic Leukemia, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8927-4125","authenticated-orcid":false,"given":"Monika","family":"Dlugosz-Danecka","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-0989","authenticated-orcid":false,"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[{"name":"Division of Experimental Oncology, Strategic Research Program on Chronic Lymphocytic Leukemia, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Lymphoid Malignancies, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Krak\u00f3w, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.8"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"CIT0003","unstructured":"Wierda WG, Byrd JC, Abramson JS, et\u00a0al. Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology [PubMed: 32023533]. 2020;18:185\u2013217."},{"key":"#cr-split#-CIT0004.1","unstructured":"ESMO Guidelines Committee. eUpdate - chronic lymphocytic leukaemia treatment recommendations 2017. [updated 2017 June 27"},{"key":"#cr-split#-CIT0004.2","unstructured":"cited 2020 July 15]. Available from: http:\/\/www.esmo.org\/Guidelines\/Haematological-Malignancies\/Chronic-Lymphocytic-Leukaemia\/eUpdate-Treatment-Recommendations."},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.169334"},{"key":"CIT0006","doi-asserted-by":"crossref","unstructured":"Ghia P, Pluta A, Wach M, et\u00a0al., editors. Acalabrutinib (Acala) vs. idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): ASCEND final results. Virtual edition of the 25th European Hematology Association Annual Meeting, EHA Library; 2020. p. S159.","DOI":"10.1200\/JCO.2020.38.15_suppl.8015"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"CIT0015","unstructured":"National Comprehensive Cancer Network. NCCN guidelines version 3.2020: chronic lymphocytic leukemia\/small lymphocytic lymphoma [2019 December 11]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf."},{"volume-title":"Imbruvica (ibrutinib) [prescribing information]","year":"2019","key":"CIT0016"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"CIT0018","unstructured":"Imbruvica (ibrutinib) [prescribing information]. Sunnyvale, CA: Pharmacyclics LLC; 2014. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205552Orig2lbl.pdf"},{"key":"CIT0019","unstructured":"AstraZeneca Pharmaceuticals LP. Calquence approved in the US for adult patients with chronic lymphocytic leukaemia [press release]; [cited 2019 December 17. Available from: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/calquence-approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html."},{"volume-title":"Calquence (acalabrutinib) [prescribing information]","key":"CIT0020"},{"key":"CIT0021","unstructured":"FDA. FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma; 2019 [cited 2020 Mar 19]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma."},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-712828"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-606038"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0313-y"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242909"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.664797"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2011.585971"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-764373"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.65"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141018"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1589"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0807082"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.343"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0250-9"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-109973"},{"issue":"15","key":"CIT0040","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1158\/1538-7445.AM2015-2596","volume":"75","author":"Covey T","year":"2015","journal-title":"Cancer Res"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1446"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018884940"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018030007"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110451"},{"issue":"15","key":"CIT0045","volume":"37","author":"Rogers KA","year":"2019","journal-title":"J Clin Oncol"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1130"},{"key":"CIT0047","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"issue":"1","key":"CIT0048","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1182\/blood-2019-123057","volume":"134","author":"Brown JR","year":"2019","journal-title":"Blood"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127506"},{"key":"CIT0050","unstructured":"Byrd JC, Woyach JA, Furman RR, et\u00a0al., editors. Acalabrutinib in treatment-na\u00efve chronic lymphocytic leukemia: mature results from phase 2 Study demonstrating durable remissions and long-term tolerability. Vol. 294983.Virtual Edition of the 25th European Hematology Association Annual Meeting. EHA Library; 2020. p. S163."},{"issue":"1","key":"CIT0051","first-page":"4326","volume":"130","author":"Byrd JC","year":"2017","journal-title":"Blood"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8064"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7521"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-846808"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.196014"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.056"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2020.1864352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,11]],"date-time":"2022-12-11T14:31:36Z","timestamp":1670769096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2020.1864352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4,16]]}},"alternative-id":["10.1080\/10428194.2020.1864352"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2020.1864352","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}